MALI
MALI Platform
AI Stock Research

Baker Bros. Advisors LP: latest 13F holdings

For the quarter ending 30 September 2026, Baker Bros. Advisors LP reported 80 positions worth $21.0B in total, filed with the SEC on 16 November 2026. The quarter before, it reported $20.0B.

Read the filing at SEC EDGAR
Checked: the cover page's entry count and total value match the holdings table.

Top 50 positions by value

#IssuerClassValueWeightSharesvs quarter before
1Incyte CorporationCOM$3.7B17.74%30,762,652Added 0.0%
2BeOne Medicines Ltd.SPONSORED ADS$3.2B15.36%8,832,335Added 0.3%
3Revolution Medicines, Inc.COM$2.2B10.38%10,637,318Cut 7.0%
4Kodiak Sciences Inc.COM$2.1B9.85%21,860,941Added 9.7%
5Madrigal Pharmaceuticals, Inc.COM$1.1B5.13%2,143,131Unchanged
6Insmed IncorporatedCOM PAR $.01$1.0B4.77%8,796,111Unchanged
7Kymera Therapeutics, Inc.COM$967.8M4.60%8,657,242Unchanged
8ACADIA Pharmaceuticals Inc.COM$864.7M4.11%42,912,904Unchanged
9GRAIL, Inc.COM$564.5M2.68%4,028,614Unchanged
10Summit Therapeutics Inc.COM$554.4M2.63%32,786,348Unchanged
11Rhythm Pharmaceuticals, Inc.COM$533.6M2.54%5,604,483Unchanged
12Praxis Precision Medicines, Inc.COM$510.6M2.43%1,753,198Unchanged
13AbCellera Biologics Inc.COM$481.6M2.29%33,012,139Added 0.0%
14Alkermes plcSHS$405.7M1.93%10,012,267Unchanged
15Celcuity Inc.COM$383.0M1.82%4,815,792Cut 39.2%
16Kiniksa Pharmaceuticals International, plcORD SHS CL A$211.5M1.00%2,834,643Unchanged
17IDEAYA Biosciences, Inc.COM$192.5M0.91%5,010,030Unchanged
18Edgewise Therapeutics, Inc.COM$150.3M0.71%3,701,719Unchanged
19Replimune Group, Inc.COM$146.2M0.69%11,045,336Unchanged
20Roivant Sciences Ltd.SHS$133.9M0.64%3,660,352Cut 22.4%
21Arrowhead Pharmaceuticals, Inc.COM$111.9M0.53%1,709,053Cut 14.2%
22Nurix Therapeutics, Inc.COM$110.5M0.52%4,658,556Unchanged
23Immunovant, Inc.COM$93.6M0.44%2,770,377Cut 49.0%
24Celldex Therapeutics, Inc.COM$83.1M0.40%2,564,984Added 116.9%
25Denali Therapeutics Inc.COM$77.2M0.37%3,734,336Unchanged
26Dianthus Therapeutics, Inc.COM$75.0M0.36%852,164Unchanged
27Celcuity Inc.Note 2.75% 8/1/2031$55.5M0.26%—New
28Rapport Therapeutics, Inc.COM$52.0M0.25%1,547,090Unchanged
29Monte Rosa Therapeutics, Inc.COM$51.8M0.25%4,345,736Unchanged
30Relay Therapeutics, Inc.COM$51.0M0.24%2,826,783Unchanged
31Ionis Pharmaceuticals, Inc.COM$45.7M0.22%1,023,864Cut 50.0%
32Structure Therapeutics Inc.SPONSORED ADS$44.8M0.21%1,432,529Unchanged
33Enliven Therapeutics, Inc.COM$41.5M0.20%905,191Unchanged
34Bicycle Therapeutics plcSPONSORED ADS$40.1M0.19%10,885,357Unchanged
35Prelude Therapeutics Inc.COM$39.6M0.19%10,123,824Unchanged
36Mirum Pharmaceuticals, Inc.COM$38.1M0.18%445,975Unchanged
37Design Therapeutics, Inc.COM$37.6M0.18%2,988,144Added 11.6%
38Immatics N.V.SHS$37.4M0.18%4,256,682Cut 55.2%
39Stoke Therapeutics, Inc.COM$34.2M0.16%1,313,999Cut 60.6%
40Entrada Therapeutics, Inc.COM$32.2M0.15%5,072,730Unchanged
41Neurogene Inc.COM$27.6M0.13%991,691Unchanged
42Xencor, Inc.COM$27.5M0.13%1,102,106Unchanged
43Faeth Therapeutics, Inc.COM$23.9M0.11%803,425Cut 37.5%
44Absci CorporationCOM$23.0M0.11%2,134,803Unchanged
45Disc Medicine, Inc.COM$22.9M0.11%349,657Unchanged
46Arcus Biosciences, Inc.COM$21.8M0.10%844,816Unchanged
47Generate Biomedicines, Inc.COM SHS$21.4M0.10%1,423,602Unchanged
48Taysha Gene Therapies, Inc.COM SHS$19.5M0.09%4,004,756Unchanged
49Aktis Oncology, Inc.COM$19.4M0.09%996,351Unchanged
50Jade Biosciences, Inc.COM$17.3M0.08%1,230,426Unchanged

Showing the largest 50 of 80 positions. Every position is in MALI's SEC Financials & 13F workspace.

New this quarter

  • Celcuity Inc. · $55.5M

Sold out

  • Crinetics Pharmaceuticals, Inc. · was $88.0M
  • Celcuity Inc. · was $69.2M
  • Alumis Inc. · was $56.6M
  • Viridian Therapeutics, Inc. · was $43.8M
  • Sionna Therapeutics, Inc. · was $17.6M
  • Verastem, Inc. · was $9.5M
  • Sagimet Biosciences Inc. · was $7.4M
  • Wave Life Sciences Ltd. · was $4.8M
  • Skye Bioscience, Inc. · was $1.1M
  • Surrozen, Inc. Warrants @ $172.50 8/11/2026 (15 FOR 1) · was $13.8K

Reading a 13F

A 13F lists a manager's long positions in US-listed securities at the end of a quarter, filed up to 45 days later. It leaves out short positions, cash and most non-US holdings, so it is a partial, delayed view of a portfolio. Nothing here is investment advice.

Positions are named as the manager filed them. Values are the filing's own, in US dollars; changes compare share counts with the quarter before.

Other managers